Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
44
MNMD Quote, Financials, Valuation and Earnings
Last price:
$12.26
Seasonality move
:
31.21%
Day range:
$12.02 - $12.77
52-week range:
$4.70 - $14.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.11x
Volume:
1.1M
Avg. volume:
1.7M
1-year change:
68.72%
Market cap:
$1.2B
Revenue:
--
EPS (TTM):
-$1.97
Analysts' Opinion
-
Consensus RatingMind Medicine (MindMed), Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.64, Mind Medicine (MindMed), Inc. has an estimated upside of 112.22% from its current price of $12.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $12.08.
Fair Value
-
According to the consensus of 8 analysts, Mind Medicine (MindMed), Inc. has 112.22% upside to fair value with a price target of $25.64 per share.
MNMD vs. S&P 500
-
Over the past 5 trading days, Mind Medicine (MindMed), Inc. has underperformed the S&P 500 by -6.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mind Medicine (MindMed), Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mind Medicine (MindMed), Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Mind Medicine (MindMed), Inc. reported revenues of --.
Earnings Growth
-
Mind Medicine (MindMed), Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Mind Medicine (MindMed), Inc. reported earnings per share of -$0.78.
Enterprise value:
1B
EV / Invested capital:
5.97x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-60.07%
Net Income Margin (TTM):
--
Return On Equity:
-80.63%
Return On Invested Capital:
-70.5%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.2M | -$1.3M | -- | -- | -- | |
| Operating Income | -$85.6M | -$93.7M | -$151.2M | -$24.8M | -$45.7M | |
| EBITDA | -$82.3M | -$92.3M | -$151.2M | -$24.8M | -$45.7M | |
| Diluted EPS | -$1.99 | -$2.09 | -$1.97 | -$0.27 | -$0.78 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $146.5M | $156.5M | $120.1M | $299.4M | $215.8M | |
| Total Assets | $178.6M | $180.9M | $141.6M | $319.8M | $236.9M | |
| Current Liabilities | $5.8M | $26M | $31.2M | $33.3M | $65.4M | |
| Total Liabilities | $12.5M | $27.3M | $45.6M | $57.6M | $106.3M | |
| Total Equity | $166M | $153.6M | $96M | $262.2M | $130.6M | |
| Total Debt | -- | -- | $14.1M | $24.3M | $40.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$55.4M | -$73.4M | -$113.9M | -$17.2M | -$29.8M | |
| Cash From Investing | -- | -- | -$189.4M | -- | $16.3M | |
| Cash From Financing | $18.4M | $250.7M | $21.3M | $69.7M | $697.6K | |
| Free Cash Flow | -$55.4M | -$73.4M | -$113.9M | -$17.2M | -$29.8M | |
MNMD
Sector
Market Cap
$1.2B
$28M
Price % of 52-Week High
83.71%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
-0.54%
-1.4%
1-Year Price Total Return
68.72%
-19%
Beta (5-Year)
2.792
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$12.49
200-day SMA
Buy
Level
$8.94
Bollinger Bands (100)
Buy
Level
9.62 - 12.46
Chaikin Money Flow
Sell
Level
-35.2M
20-day SMA
Buy
Level
$11.99
Relative Strength Index (RSI14)
Sell
Level
49.30
ADX Line
Buy
Level
17.44
Williams %R
Neutral
Level
-75.6906
50-day SMA
Sell
Level
$12.23
MACD (12, 26)
Buy
Level
0.15
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
69.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1475)
Sell
CA Score
(Annual)
Level (-1.5186)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.6133)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, MNMD has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNMD average analyst price target in the past 3 months is $25.64.
-
Where Will Mind Medicine (MindMed), Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mind Medicine (MindMed), Inc. share price will rise to $25.64 per share over the next 12 months.
-
What Do Analysts Say About Mind Medicine (MindMed), Inc.?
Analysts are divided on their view about Mind Medicine (MindMed), Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mind Medicine (MindMed), Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Mind Medicine (MindMed), Inc.'s Price Target?
The price target for Mind Medicine (MindMed), Inc. over the next 1-year time period is forecast to be $25.64 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mind Medicine (MindMed), Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNMD?
You can purchase shares of Mind Medicine (MindMed), Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mind Medicine (MindMed), Inc. shares.
-
What Is The Mind Medicine (MindMed), Inc. Share Price Today?
Mind Medicine (MindMed), Inc. was last trading at $12.26 per share. This represents the most recent stock quote for Mind Medicine (MindMed), Inc.. Yesterday, Mind Medicine (MindMed), Inc. closed at $12.08 per share.
-
How To Buy Mind Medicine (MindMed), Inc. Stock Online?
In order to purchase Mind Medicine (MindMed), Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MNMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MNMD
Sector
P/E ratio
--
24.31x
PEG ratio
--
-0.01x
P/B ratio
9.11x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
MNMD
Sector
Revenue growth
--
4.6%
Earnings growth
-185.11%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.50
-$0.20
Profitability
MNMD
Sector
Profitability FY 2024
-$527K
$3.5M
Return on invested capital
-70.5%
-31.66%
Return on assets
-60.07%
-27.84%
Return on equity
-80.63%
-37.28%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
MNMD
Sector
Total cash
$209.1M
$26.8M
Short term investments
--
$26M
Total assets
$302.2M
$78.7M
Long term debt
$40.4M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
